155 related articles for article (PubMed ID: 31719663)
1. Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy.
Marascio J; Spratt DE; Zhang J; Trabulsi EJ; Le T; Sedzorme WS; Beeler WH; Davicioni E; Dabbas B; Lin DW; Gore JL; Bloom M; Mann M; Mark JR; Calvaresi A; Godwin JL; McCue P; Hurwitz MD; Kelly WK; Lallas CD; Knudsen KE; Gomella LG; Dicker AP; Den RB
Prostate Cancer Prostatic Dis; 2020 Jun; 23(2):295-302. PubMed ID: 31719663
[TBL] [Abstract][Full Text] [Related]
2. Effect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgery.
Badani KK; Thompson DJ; Brown G; Holmes D; Kella N; Albala D; Singh A; Buerki C; Davicioni E; Hornberger J
BJU Int; 2015 Mar; 115(3):419-29. PubMed ID: 24784420
[TBL] [Abstract][Full Text] [Related]
3. Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group.
Badani K; Thompson DJ; Buerki C; Davicioni E; Garrison J; Ghadessi M; Mitra AP; Wood PJ; Hornberger J
Oncotarget; 2013 Apr; 4(4):600-9. PubMed ID: 23592338
[TBL] [Abstract][Full Text] [Related]
4. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
[TBL] [Abstract][Full Text] [Related]
5. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
[TBL] [Abstract][Full Text] [Related]
6. Influence of a genomic classifier on post-operative treatment decisions in high-risk prostate cancer patients: results from the PRO-ACT study.
Michalopoulos SN; Kella N; Payne R; Yohannes P; Singh A; Hettinger C; Yousefi K; Hornberger J;
Curr Med Res Opin; 2014 Aug; 30(8):1547-56. PubMed ID: 24803160
[TBL] [Abstract][Full Text] [Related]
7. Validation of a genomic classifier for prediction of metastasis and prostate cancer-specific mortality in African-American men following radical prostatectomy in an equal access healthcare setting.
Howard LE; Zhang J; Fishbane N; Hoedt AM; Klaassen Z; Spratt DE; Vidal AC; Lin D; Hitchins MP; You S; Freeman MR; Yamoah K; Davicioni E; Freedland SJ
Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):419-428. PubMed ID: 31844180
[TBL] [Abstract][Full Text] [Related]
8. Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PRO-IMPACT study.
Gore JL; du Plessis M; Santiago-Jiménez M; Yousefi K; Thompson DJS; Karsh L; Lane BR; Franks M; Chen DYT; Bandyk M; Bianco FJ; Brown G; Clark W; Kibel AS; Kim HL; Lowrance W; Manoharan M; Maroni P; Perrapato S; Sieber P; Trabulsi EJ; Waterhouse R; Davicioni E; Lotan Y; Lin DW
Cancer; 2017 Aug; 123(15):2850-2859. PubMed ID: 28422278
[TBL] [Abstract][Full Text] [Related]
9. Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy.
Freedland SJ; Choeurng V; Howard L; De Hoedt A; du Plessis M; Yousefi K; Lam LL; Buerki C; Ra S; Robbins B; Trabulsi EJ; Shah NL; Abdollah F; Feng FY; Davicioni E; Dicker AP; Karnes RJ; Den RB
Eur Urol; 2016 Oct; 70(4):588-596. PubMed ID: 26806658
[TBL] [Abstract][Full Text] [Related]
10. Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease.
Spratt DE; Yousefi K; Deheshi S; Ross AE; Den RB; Schaeffer EM; Trock BJ; Zhang J; Glass AG; Dicker AP; Abdollah F; Zhao SG; Lam LLC; du Plessis M; Choeurng V; Haddad Z; Buerki C; Davicioni E; Weinmann S; Freedland SJ; Klein EA; Karnes RJ; Feng FY
J Clin Oncol; 2017 Jun; 35(18):1991-1998. PubMed ID: 28358655
[TBL] [Abstract][Full Text] [Related]
11. External validation of genomic classifier-based risk-stratification tool to identify candidates for adjuvant radiation therapy in patients with prostate cancer.
Lee DI; Shahait M; Dalela D; Keeley J; Lal P; Vapiwala N; Abdollah F
World J Urol; 2021 Sep; 39(9):3217-3222. PubMed ID: 33388922
[TBL] [Abstract][Full Text] [Related]
12. Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery.
Van den Broeck T; Moris L; Gevaert T; Tosco L; Smeets E; Fishbane N; Liu Y; Helsen C; Margrave J; Buerki C; Davicioni E; Van Poppel H; Everaerts W; Weinmann S; Den R; Davis J; Schaeffer E; Karnes RJ; Claessens F; Joniau S
Eur Urol Oncol; 2019 Sep; 2(5):589-596. PubMed ID: 31411980
[TBL] [Abstract][Full Text] [Related]
13. Genomic Classifier Augments the Role of Pathological Features in Identifying Optimal Candidates for Adjuvant Radiation Therapy in Patients With Prostate Cancer: Development and Internal Validation of a Multivariable Prognostic Model.
Dalela D; Santiago-Jiménez M; Yousefi K; Karnes RJ; Ross AE; Den RB; Freedland SJ; Schaeffer EM; Dicker AP; Menon M; Briganti A; Davicioni E; Abdollah F
J Clin Oncol; 2017 Jun; 35(18):1982-1990. PubMed ID: 28350520
[TBL] [Abstract][Full Text] [Related]
14. Subpathologies and genomic classifier for treatment individualization of post-prostatectomy radiotherapy.
Ramotar M; Chua MLK; Truong H; Hosni A; Pintilie M; Davicioni E; Fleshner NE; Dicker AP; Bristow RG; He HH; van der Kwast T; Den RB; Berlin A
Urol Oncol; 2022 Jan; 40(1):5.e1-5.e13. PubMed ID: 34538726
[TBL] [Abstract][Full Text] [Related]
15. Clinical Utility of a Genomic Classifier in Men Undergoing Radical Prostatectomy: The PRO-IMPACT Trial.
Gore JL; du Plessis M; Zhang J; Dai D; Thompson DJS; Karsh L; Lane B; Franks M; Chen DYT; Bianco FJ; Brown G; Clark W; Kibel AS; Kim H; Lowrance W; Manoharan M; Maroni P; Perrapato S; Sieber P; Trabulsi EJ; Waterhouse R; Spratt DE; Davicioni E; Lotan Y; Lin DW
Pract Radiat Oncol; 2020; 10(2):e82-e90. PubMed ID: 31761540
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of post-operative radiation in a prostatectomy cohort adjusted for clinical and genomic risk.
Ross AE; Den RB; Yousefi K; Trock BJ; Tosoian J; Davicioni E; Thompson DJ; Choeurng V; Haddad Z; Tran PT; Trabulsi EJ; Gomella LG; Lallas CD; Abdollah F; Feng FY; Klein EA; Dicker AP; Freedland SJ; Karnes RJ; Schaeffer EM
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):277-82. PubMed ID: 27136742
[TBL] [Abstract][Full Text] [Related]
17. Use of the Decipher genomic classifier among men with prostate cancer in the United States.
Zaorsky NG; Proudfoot JA; Jia AY; Zuhour R; Vince R; Liu Y; Zhao X; Hu J; Schussler NC; Stevens JL; Bentler S; Cress RD; Doherty JA; Durbin EB; Gershman S; Cheng I; Gonsalves L; Hernandez BY; Liu L; Morawski BM; Schymura M; Schwartz SM; Ward KC; Wiggins C; Wu XC; Shoag JE; Ponsky L; Dal Pra A; Schaeffer EM; Ross AE; Sun Y; Davicioni E; Petkov V; Spratt DE
JNCI Cancer Spectr; 2023 Aug; 7(5):. PubMed ID: 37525535
[TBL] [Abstract][Full Text] [Related]
18. Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy.
Spratt DE; Dai DLY; Den RB; Troncoso P; Yousefi K; Ross AE; Schaeffer EM; Haddad Z; Davicioni E; Mehra R; Morgan TM; Rayford W; Abdollah F; Trabulsi E; Achim M; Tapia ELN; Guerrero M; Karnes RJ; Dicker AP; Hurwitz MA; Nguyen PL; Feng FFY; Freedland SJ; Davis JW
Eur Urol; 2018 Jul; 74(1):107-114. PubMed ID: 29233664
[TBL] [Abstract][Full Text] [Related]
19. Defining Prostate Cancer at Favorable Intermediate Risk: The Potential Utility of Magnetic Resonance Imaging and Genomic Tests.
Falagario UG; Beksac AT; Martini A; Cumarasamy S; Gupta A; Prasad S; Thulasidass H; Shah QN; Jayaratna I; Lewis S; Rastinehad AR; Taouli B; Cormio L; Carrieri G; Tewari AK
J Urol; 2019 Jul; 202(1):102-107. PubMed ID: 30730408
[TBL] [Abstract][Full Text] [Related]
20. The Clinical Utility of the Genomic Prostate Score in Men with Very Low to Intermediate Risk Prostate Cancer.
Gaffney C; Golan R; Cantu MD; Scognamiglio T; McCarthy H; Mosquera JM; McClure TD; Barbieri CE; Robinson BD; Khani F
J Urol; 2019 Jul; 202(1):96-101. PubMed ID: 30933552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
